[go: up one dir, main page]

YU22401A - Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom - Google Patents

Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Info

Publication number
YU22401A
YU22401A YU22401A YU22401A YU22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A YU 22401 A YU22401 A YU 22401A
Authority
YU
Yugoslavia
Prior art keywords
combination
capecytabine
acetyldynaline
cisplatinium
gemcytabine
Prior art date
Application number
YU22401A
Other languages
English (en)
Inventor
William Richard Grove
Wayne Daniel Klohs
Ronald Lynn Merriman
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU22401A publication Critical patent/YU22401A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Acetildinalin, u kombinaciji sa gemcitabinom, njegovom farmaceutski prihvatljivom solju, capecitabinom ili cisplatinom, je sinergična kombinacija agenasa koja se koristi za dobijanje leka za kancer
YU22401A 1998-09-25 1999-07-08 Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom YU22401A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
YU22401A true YU22401A (sh) 2004-03-12

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
YU22401A YU22401A (sh) 1998-09-25 1999-07-08 Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Country Status (34)

Country Link
US (3) US6469058B1 (sh)
EP (1) EP1115391B1 (sh)
JP (1) JP2002525320A (sh)
KR (1) KR20010075348A (sh)
CN (1) CN1319009A (sh)
AP (1) AP2001002109A0 (sh)
AT (1) ATE225655T1 (sh)
AU (1) AU762079B2 (sh)
BG (1) BG105470A (sh)
BR (1) BR9913952A (sh)
CA (1) CA2342981A1 (sh)
CZ (1) CZ2001905A3 (sh)
DE (1) DE69903458T2 (sh)
DK (1) DK1115391T3 (sh)
EA (1) EA200100369A1 (sh)
EE (1) EE200100187A (sh)
ES (1) ES2185378T3 (sh)
GE (1) GEP20043199B (sh)
HK (1) HK1040190A1 (sh)
HR (1) HRP20010225B1 (sh)
HU (1) HUP0103640A3 (sh)
ID (1) ID30046A (sh)
IL (1) IL141951A0 (sh)
IS (1) IS5888A (sh)
NO (1) NO20011493L (sh)
NZ (1) NZ510504A (sh)
OA (1) OA11659A (sh)
PL (1) PL348673A1 (sh)
PT (1) PT1115391E (sh)
SK (1) SK3602001A3 (sh)
TR (1) TR200100859T2 (sh)
WO (1) WO2000018393A1 (sh)
YU (1) YU22401A (sh)
ZA (1) ZA200102233B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CA2632078C (en) * 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
RU2240117C1 (ru) * 2003-04-01 2004-11-20 Алтайский государственный медицинский университет Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
CA2616306A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for processing data relating to a radiation therapy treatment plan
AU2006272742A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
JP2009502252A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 生物学的モデルに基づいて放射線療法治療プランを適合させるための方法およびシステム
KR20080039919A (ko) 2005-07-22 2008-05-07 토모테라피 인코포레이티드 방사선 치료를 받는 환자의 호흡 상태를 검출하는 시스템및 방법
JP2009514559A (ja) 2005-07-22 2009-04-09 トモセラピー・インコーポレーテッド 線量体積ヒストグラムを用いて輪郭構造を生成するシステムおよび方法
CA2616299A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method of placing constraints on a deformation map and system for implementing same
EP1907968A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc METHOD AND SYSTEM FOR EVALUATING QUALITY ASSURANCE CRITERIA FOR A TREATMENT ADMINISTRATION PROGRAM
CA2616309A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method of and system for predicting dose delivery
JP2009502251A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 放射線治療システムによって送達された線量を評価するシステム及び方法
AU2006272746A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating delivered dose
CN101267767A (zh) 2005-07-23 2008-09-17 断层放疗公司 使用机架和治疗床的协同运动的放射疗法成像和实施
RU2009111605A (ru) * 2006-08-31 2010-10-10 Спектрум Фармасьютикалз, Инк. (Us) Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина
CN104689336A (zh) * 2008-01-28 2015-06-10 那野伽利阿株式会社 医药组合物或组合剂
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
ES2593088T3 (es) 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
WO2020028392A1 (en) 2018-07-30 2020-02-06 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (en) * 1997-04-24 1998-10-29 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom

Also Published As

Publication number Publication date
ID30046A (id) 2001-11-01
DK1115391T3 (da) 2003-02-10
AU5092199A (en) 2000-04-17
SK3602001A3 (en) 2002-07-02
BG105470A (en) 2001-12-29
EA200100369A1 (ru) 2001-10-22
HK1040190A1 (zh) 2002-05-31
ES2185378T3 (es) 2003-04-16
EE200100187A (et) 2002-08-15
CA2342981A1 (en) 2000-04-06
AP2001002109A0 (en) 2001-03-31
DE69903458T2 (de) 2003-07-10
PL348673A1 (en) 2002-06-03
GEP20043199B (en) 2004-03-25
EP1115391B1 (en) 2002-10-09
US20030170300A1 (en) 2003-09-11
CZ2001905A3 (cs) 2001-08-15
JP2002525320A (ja) 2002-08-13
HUP0103640A2 (en) 2002-06-29
TR200100859T2 (tr) 2001-08-21
NZ510504A (en) 2003-09-26
HRP20010225B1 (en) 2004-10-31
WO2000018393A1 (en) 2000-04-06
KR20010075348A (ko) 2001-08-09
EP1115391A1 (en) 2001-07-18
NO20011493L (no) 2001-05-23
IS5888A (is) 2001-03-14
ZA200102233B (en) 2002-06-18
US6469058B1 (en) 2002-10-22
DE69903458D1 (de) 2002-11-14
OA11659A (en) 2004-12-08
AU762079B2 (en) 2003-06-19
BR9913952A (pt) 2001-06-12
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
US20030086965A1 (en) 2003-05-08
NO20011493D0 (no) 2001-03-23
PT1115391E (pt) 2003-02-28
HRP20010225A2 (en) 2002-04-30
ATE225655T1 (de) 2002-10-15
CN1319009A (zh) 2001-10-24

Similar Documents

Publication Publication Date Title
YU22401A (sh) Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
BR9911682A (pt) Metano sulfonato de paroxetina
PT929516E (pt) Derivados da benzamidina e sua utilizacao em composicoes farmaceuticas com efeito antagonista da ltb4
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
CY1108918T1 (el) Φαρμακευτικοι συνδυασμοι οξυκωδονης και ναλοξονης
BR9604951A (pt) Composição farmacêutica contendo derivados den n-fosfonoglicina par inibir o desenvolvimento de viroses e cânceres
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
FR2744918B1 (fr) Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
DK0902789T3 (da) Androstenderivater
YU64602A (sh) Smeša koja se sastoji od kamptotecina i derivata pirimidina za terapiju kancera
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
PT1105006E (pt) Incorporacao de agentes de modificacao do fumo em barras de material para fumar
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
SE9802208D0 (sv) Novel compounds
BR9809571A (pt) Composição medicinal e processo para produzì-la
DE60013486D1 (de) Verbindungen
NO20000462L (no) 4-okso-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamid derivater, deres fremstilling og deres anvendelse i terapi
ES2186596T1 (es) Uso de inhibidores de il-18.
NO970178D0 (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
EA200100214A1 (ru) Применение производных камптотецина с пониженной гастроинтестинальной токсичностью
BR8903219A (pt) Composicoes e formulacoes de aditivos bem como sua utilizacao em combustivel
BR0114604A (pt) Tratamento de c‰nceres
IT1277897B1 (it) Uso della l-carnitina,di suoi derivati e di loro sali farmaceuticamen- te accettabili in combinazione con farmaci antiretrovirali per ridurre